These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35689489)

  • 21. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
    Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
    Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Shin J; Dan K; Han D; Kim JW; Kim KK; Koh Y; Shin DY; Hong J; Yoon SS; Park S; Song SH; Kim I
    Blood Cells Mol Dis; 2019 Feb; 74():5-12. PubMed ID: 30344086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation.
    Salmasian H; Rohanizadegan M; Banihosseini S; Rahimi Darabad R; Rabbani-Anari M; Shakiba A; Ferrara JL
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD005565. PubMed ID: 20091579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
    Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
    Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
    J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
    Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
    Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
    Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
    Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
    Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.
    McCaul KG; Nevill TJ; Barnett MJ; Toze CL; Currie CJ; Sutherland HJ; Conneally EA; Shepherd JD; Nantel SH; Hogge DE; Klingemann HG
    J Hematother Stem Cell Res; 2000 Jun; 9(3):367-74. PubMed ID: 10894358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
    Lee SJ; Zahrieh D; Agura E; MacMillan ML; Maziarz RT; McCarthy PL; Ho VT; Cutler C; Alyea EP; Antin JH; Soiffer RJ
    Blood; 2004 Sep; 104(5):1559-64. PubMed ID: 15138163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease.
    Rodriguez-Otero P; Porcher R; Peffault de Latour R; Contreras M; Bouhnik Y; Xhaard A; Andreoli A; Ribaud P; Kapel N; Janin A; Socié G; Robin M
    Blood; 2012 Jun; 119(24):5909-17. PubMed ID: 22555971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.
    Spałek A; Wieczorkiewicz-Kabut A; Koclęga A; Woźniczka K; Węglarz P; Boral K; Kata D; Zielińska P; Helbig G
    Int J Hematol; 2022 Dec; 116(6):922-928. PubMed ID: 35972605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
    Lazarus HM; Sommers SR; Arfons LM; Fu P; Ataergin SA; Kaye NM; Liu F; Kindwall-Keller TL; Cooper BW; Laughlin MJ; Creger RJ; Barr PM; Gerson SL; Kaplan D
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):970-8. PubMed ID: 21440080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
    Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.